Last reviewed · How we verify
Early Highly Effective Therapies Group
Early Highly Effective Therapies Group works by targeting the underlying causes of various diseases.
Early Highly Effective Therapies Group works by targeting the underlying causes of various diseases. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | Early Highly Effective Therapies Group |
|---|---|
| Also known as | Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab) |
| Sponsor | The Cleveland Clinic |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
While the exact mechanism is not well-documented, it is believed to involve a combination of immunomodulatory and anti-inflammatory effects. This allows the drug to modulate the body's response to disease, leading to improved outcomes.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU. (NA)
- PulmoSalud: Multimodal Program for Prehabilitation and Early Home Rehabilitation in Patients With Lung Cancer (NA)
- A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PHASE2)
- Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis (PHASE4)
- A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population (PHASE2)
- Effectiveness of Percutaneous Electrolysis in Subacute and Early Chronic Medial Gastrocnemius Muscle Injuries (NA)
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
- A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Early Highly Effective Therapies Group CI brief — competitive landscape report
- Early Highly Effective Therapies Group updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI